Very disappointed - I must say!
Russia sounds interesting - but to call that a pharma major? Guess for the region that be right.
Positive: they have to drive development and approval themselves and will be a test case for other drugs to potentially grant further licenses
TMC: very clearly spelt out: STI can't afford to keep and develop it. So it needs to be JV'd or sold - so where does that leave the previously mentioned India deal and placement in STI?
Canada plant: looks like that may carry itself ultimately with further contract being negotiated
AIM listing: further dilution over what little will be left but looks like we need it to be able to off-load assets and/or drive what is left (HDA etc)
O'Connel ST properties: sell to clear debt
KidneyVital: just about the only vital part of STI right now and hopefully will launch well and start spinning money
Cool and hard assessment between the lines - and about time to come clean on these issues.
It' going to be an interesting ride!
My sentiment will revert to : NONE
ann out, page-7
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)